TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2154430
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg every 12 h for seven days)
Study: 426993
Drug: Pancuronium 0.02‐0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.02‐0.08 mg kg‐1
Study: 426993
Drug: Fentanyl 0.003
Normalized name: fentanyl 0.003 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.003 mg kg‐1 plus droperidol 0.15 mg kg‐1
Study: 426993
Drug: Fentanyl 0.003
Normalized name: fentanyl 0.003 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.003 mg kg‐1
Study: 23517287
Drug: pegylated‐IFNα2a weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated‐IFNα2a weekly or albumin‐IFNα2b every 2 weeks for up to 24 weeks
Study: 16287396
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy for Sexual Abuse Survivors (CPT‐SA)
Study: 8788692
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment (intensive seven-day-a-week neurobehavioral treatment model program)
Study: 8788692
Drug: Traditional outpatient
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional outpatient treatment (conventional five-day-a-week program)
Study: 2405746
Drug: Inhaled pirbuterol
Normalized name: pirbuterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled pirbuterol
Study: 155297
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta 2-sympathomimetic (salbutamol or fenoterol) and SCH 1000
Study: 29235507
Drug: Liraglutide (GLP-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (GLP-1 analog), 6 months treatment
Study: 23886886
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT) - observing video sequences of unimanual or bimanual goal-directed actions for 1 hour per day for 3 weeks followed by execution of observed actions
Study: 21402628
Drug: 24% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% sucrose solution orally
Study: 21402628
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of liposomal lidocaine cream topically
Study: 19359148
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (12.3 mmol or 300 mg of elemental magnesium in the form of magnesium oxide, n=75)
Study: 17349076
Drug: Meat-containing meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat-containing meal with mustard (3 g)
Study: 17349076
Drug: Non meat-containing
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non meat-containing meal with mustard (3 g)
Study: 10356434
Drug: Experience with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experience with dental injections
Study: 7989975
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (0.85‐9.55 GBq or 23‐258 mCi of 131I)
Study: 2670220
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (captopril, enalapril, quinapril)
Study: 28719834
Drug: After one
Approvals — FDA: no, EMA: no, PMDA: no
Description: After one year of GH therapy
Study: 25150178
Drug: Bosentan treatment
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan treatment for 12 weeks
Study: 18327133
Drug: Vitrectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrectomy with ILM peeling followed by IVTA injection
Study: 7977090
Drug: Felodipine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine, 5 mg once daily
Study: 7977090
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN), 20 mg twice daily
Study: 3197098
Drug: Dihydroergotamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (10 mg) + Acetylsalicylic acid (80 mg)
Study: 29468817
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL regular coffee containing 34.8 μmol nicotinic acid (NA) and 0.58 μmol nicotinamide (NAM)
Study: 25834948
Drug: 10-mg idursulfase-IT
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10-mg idursulfase-IT
Study: 25834948
Drug: 30-mg idursulfase-IT
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30-mg idursulfase-IT
Study: 25834948
Drug: 1-mg idursulfase-IT
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1-mg idursulfase-IT
Study: 19892540
Drug: Tiotropium 18μg
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18μg inhalation capsules once daily
Study: 19892540
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation capsules once daily
Study: 18375477
Drug: Plasma butyrylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in chlorpyrifos poisoning
Study: 18375477
Drug: Plasma butyrylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in dimethoate poisoning
Study: 11430713
Drug: Group motor
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group motor skill intervention, once weekly for 10 weeks
Study: 9566656
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (2.5 to 7.5 mg based on body weight)
Study: 8110567
Drug: 1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ropivacaine 10 ml
Study: 8110567
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine 20 ml
Study: 8110567
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 20 ml
Study: 27352003
Drug: Dexmedetomidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (50 μg kg−1) and midazolam (0.45 mg kg−1)
Study: 27352003
Drug: Dexmedetomidine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (30 μg kg−1), midazolam (0.45 mg kg−1) and butorphanol (0.25 mg kg−1)
Study: 15677411
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) + Diet for 6 weeks
Study: 15677411
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) + Diet
Study: 11350261
Drug: MCT (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT (medium chain triglycerides) 15 mL h(‐1)
Study: 11350261
Drug: MCT (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT (medium chain triglycerides) 30 mL h(‐1)
Study: 7639370
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 25 mL of 0.75% bupivacaine
Study: 7639370
Drug: Staged injection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staged injection of 25 mL of 0.75% bupivacaine
Study: 20473734
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with Jinlong Capsule (JLC) and transcatheter arterial chemoembolization (TACE)
Study: 12728024
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (posterior or anterior arthrodesis and instrumentation)
Study: 12728024
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (application of a body cast or orthosis)
Study: 8772681
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab (antiplatelet IIb/IIIa receptor antibody)
Study: 29458237
Drug: Irinotecan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (80 mg/m2, days 1 and 8) plus capecitabine (1,000 mg/m2 twice a day, days 1-14)
Study: 29458237
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (1,250 mg/m2 twice a day, days 1-14)
Study: 29393675
Drug: Dual-hormone artificial
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual-hormone artificial pancreas (hypoglycemia awareness)
Study: 29393675
Drug: Single-hormone artificial
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-hormone artificial pancreas (hypoglycemia awareness)
Study: 26741052
Drug: Topical naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical naltrexone (1 drop, 4 drops) at dosages of 1 × 10(‐6) M, 5 × 10(‐6) M, 1 × 10(‐5) M, 5 × 10(‐5) M
Study: 25005652
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (varenicline + nicotine patch)
Study: 23270509
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care and standard care
Study: 21062129
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg) plus Ivermectin (200 μg/kg)
Study: 21062129
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) plus Ivermectin (200 μg/kg)
Study: 21062129
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg) plus placebo
Study: 21062129
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) plus placebo
Study: 28369530
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 μg/kg)
Study: 19633577
Drug: Balsalazide 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 6.75 g/day
Study: 12492193
Drug: Mesalamine 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 2.4 g/day
Study: 7649071
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with trihexyphenidyle (group III)
Study: 2539772
Drug: Thymostimulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (1 mg/Kg i.m., days 7-14 of every cycle)
Study: 334808
Drug: Phenytoin 100
Normalized name: phenytoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 100 mg every 8 hours for two weeks
Study: 26865602
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg twice a day for 2 months with prayer (group B)
Study: 26865602
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg twice a day for 2 months (group A)
Study: 23608721
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of daily vitamin D3
Study: 23608721
Drug: 1,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 IU of daily vitamin D3
Study: 19793473
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (group 2)
Study: 12958610
Drug: Triacylglycerol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triacylglycerol infusion [1.5 ml/min]/heparin [0.2 IU/(kg.min)] (LIP)
Study: 12958610
Drug: Saline/heparin (HEP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/heparin (HEP)
Study: 9177404
Drug: Calcium Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Supplementation (CS; 500 mg/day)
Study: 3522483
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of acetylsalicylic acid
Study: 23620943
Drug: TCM herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM herbal cupping therapy
Study: 23620943
Drug: Thermal compressing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal compressing therapy
Study: 23620943
Drug: Mecobalamine (western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamine (western medicine)
Study: 21480107
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg of hepatitis B vaccine intramuscularly at birth (0), 2 and 9‐12 months of life
Study: 21480107
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine at 0, 1 and 6 months of life
Study: 11468543
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg once daily)
Study: 24576196
Drug: Titration (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration (15 mcg/m(2) s.c. three times weekly during week 1, 30 mcg/m(2) s.c. three times weekly during week 2, followed by 50 mcg/m(2) s.c. three times weekly during week 3)
Study: 24576196
Drug: No Titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Titration (full 50 mcg/m(2) s.c. three times weekly for 3 weeks)
Study: 24576196
Drug: Titration
Normalized name: Rebif Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration
Study: 24576196
Drug: Titration and
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration and No Titration
Study: 16549837
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 plus aprinocarsen 2 mg/kg/d as continuous infusion for 14 days
Study: 16549837
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1
Study: 9266531
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 administered as a meal (30 mg/person)
Study: 9266531
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 administered as capsules (30 mg/person)
Study: 9266531
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (both forms of administration)
Study: 22158731
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46)
Study: 22158731
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg phentermine/92 mg controlled-release topiramate (15/92)
Study: 18512557
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg amikacin administered at 3-4 postburn hours (A group)
Study: 18512557
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg amikacin administered at 10 postburn hours (B group)
Study: 18512557
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg amikacin administered at 20 postburn hours (C group)
Study: 18512557
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg amikacin administered at 30 postburn hours (D group)
Study: 12100328
Drug: Na-P preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-P preparation
Study: 12100328
Drug: PEG preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG preparation
Study: 9842950
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (titrated to a maximum of 200 mg/d for 12 weeks)
Study: 8128938
Drug: IV bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus of p‐aminohippurate (PAH) 10 mg/kg
Study: 8128938
Drug: IV bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus of phenolsulfonphthalein (PSP) 1 mg/kg
Study: 8128938
Drug: Standard constant‐rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard constant‐rate IV infusion of PAH
Study: 2918184
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy with Gi-rep (MW 106,000)
Study: 2918184
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy with Ei-M (MW 22,800)
Study: 2918184
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy with DIIIa (MW 9980)
Study: 2918184
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy (all antigens)
Study: 2918184
Drug: Hyposensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyposensitization therapy
Study: 791105
Drug: mannitol (M),
Approvals — FDA: no, EMA: no, PMDA: no
Description: mannitol (M), 1 g/kg
Study: 791105
Drug: amphotericin B,
Normalized name: Amphotericin B, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: amphotericin B, 1 mg/kg
Study: 11557169
Drug: Physostigmine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine augmentation
Study: 29855372
Drug: Alpha Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Brain nootropic supplement (1925 mg, 3 pills per day: 2 pills at breakfast, 1 pill at dinner)
Study: 29855372
Drug: Alpha Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Brain nootropic supplement
Study: 27694266
Drug: VKA (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA (Vitamin K Antagonists)
Study: 22035647
Drug: Preoperative counseling
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative counseling (Treatment group)
Study: 20136176
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant (CI) listeners
Study: 16351674
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (2 cc of 10 mg)
Study: 16351674
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 cc)
Study: 12851665
Drug: Enhanced Pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Pharmaceutical Care (EC)
Study: 10349117
Drug: Intravenous diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diphenhydramine (DPH)
Study: 10349117
Drug: Oral diphenhydramine
Normalized name: diphenhydramine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diphenhydramine (DPH)
Study: 10349117
Drug: Functional score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional score after oral DPH
Study: 2019162
Drug: Albuterol, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol, 90 micrograms by inhalation four times a day
Study: 19224365
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment (EBT) for child PTSD
Study: 12063523
Drug: Nasal glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucocorticoid (fluticasone propionate aqueous nasal spray [FPANS], 200 microg/d)
Study: 12063523
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of montelukast (10 mg/d) and antihistamine (loratadine, 10 mg/d)
Study: 9802705
Drug: Biodegradable controlled-release
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable controlled-release delivery system containing doxycycline hyclate (8.5% w/w)
Study: 9802705
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (200 mg on day 0, then 100 mg/day for 7 days)
Study: 404157
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) 50 U i.v. followed by 2 U/min infusion for 60-90 min
Study: 17692922
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg single dose)
Study: 17692922
Drug: Boric acid
Normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boric acid suppositories (600 mg daily for 14 days)
Study: 15155324
Drug: IV parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IV parecoxib 40 mg followed by oral valdecoxib 40 mg
Study: 9862047
Drug: Neoadjuvant chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoendocrine therapy (mitozantrone and methotrexate (+/‐ mitomycin‐C) combined with tamoxifen)
Study: 9862047
Drug: Neoadjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and adjuvant therapy
Study: 7832334
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg orally)
Study: 7832334
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg/70 kg intravenously)
Study: 7832334
Drug: Propofol (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (70 mg/70 kg intravenously)
Study: 226565
Drug: Sotalol 960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 960 mg
Study: 19296248
Drug: Preventive enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive enteral nutrition (EN) - 1000 ml Nutrison Multi Fibre (4184 kJ/L) for 3 days before surgery
Study: 15170367
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg single dose
Study: 15170367
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg multiple doses (once monthly)